利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.058 秒)

    PHARMACEUTICAL COMPOSITION AND A METHOD FOR TREATMENT OF PROSTATE CANCER
    6.
    发明申请
    PHARMACEUTICAL COMPOSITION AND A METHOD FOR TREATMENT OF PROSTATE CANCER 审中-公开
    药物组合物和治疗前列腺癌的方法

    公开(公告)号：US20100297760A1

    公开(公告)日：2010-11-25

    申请号：US12714016

    申请日：2010-02-26

    申请人： Swati Sinha ,  Bikas Chandra Pal ,  Samir Bhattacharya

    发明人： Swati Sinha ,  Bikas Chandra Pal ,  Samir Bhattacharya

    IPC分类号： C12N5/02

    CPC分类号： A61K31/407 ,  A61K36/185 ,  A61K36/75 ,  A61K2300/00

    摘要： The present invention is directed to pharmaceutical compositions and methods for treatment of prostate cancer in a subject. The pharmaceutical composition includes a therapeutically effective amount of compound mahanine, or derivatives, or analogues, or pharmaceutically acceptable salt thereof. The present invention is further directed to a method of isolating compound mahanine from Murraya koenigii.

    摘要翻译： 本发明涉及用于治疗受试者的前列腺癌的药物组合物和方法。 药物组合物包括治疗有效量的化合物mahanine或其衍生物或类似物或其药学上可接受的盐。 本发明进一步涉及从柯氏乳杆菌（Murraya koenigii）分离化合物mahanine的方法。

    Process for the isolation of organic compounds useful for the treatment of cancer
    7.
    发明授权
    Process for the isolation of organic compounds useful for the treatment of cancer 有权
    用于分离可用于治疗癌症的有机化合物的方法

    公开(公告)号：US08637679B2

    公开(公告)日：2014-01-28

    申请号：US13416930

    申请日：2012-03-09

    申请人： Chitra Mandal ,  Bikas Chandra Pal ,  Kaushik Bhattacharya ,  Suman Kumar Samanta ,  Sayantani Sarkar ,  Ranjita Das

    发明人： Chitra Mandal ,  Bikas Chandra Pal ,  Kaushik Bhattacharya ,  Suman Kumar Samanta ,  Sayantani Sarkar ,  Ranjita Das

    IPC分类号： C07D491/052

    CPC分类号： A61K31/407 ,  A61K36/75 ,  A61K2236/39 ,  C07D491/052

    摘要： The present invention relates to two main components, mahanine and mahanimbine (dehydroxy-mahanine) from Murraya koenigii for the treatment of glioblastoma and cervical carcinoma. Mahanimbine exhibited anti-cancer activity against lymphoid leukemia, myeloid leukemia, glioma, cervical carcinoma, pancreatic, colon and lung cancers in nineteen cells of different genetic status. C-3 hydroxy and NH groups are responsible contributing groups for their cytotoxicity. Mahanine reduced the doses of cisplatin and paclitaxel in cervical cancer showing better efficacy and useful as an adjunct chemotherapeutic agent to reduce toxicity these two drugs. A new cheap process for this preparation was established. EtOAc extract containing alkaloids enriched with mahanimbine and mahanine, is active against glioma and cervical cancers. Mahanine is targeting the chaperone Hsp90 which led to the proteasome-dependent degradation of several Hsp90-client proteins in diverse carcinoma types, glioblastoma, cervical carcinoma and pancreatic adenocarcinoma irrespective of their tissue origins thereby killing the cancer cells.

    摘要翻译： 本发明涉及两种主要成分，来自Murraya koenigii的mahanine和mahanimbine（dehydroxy-mahanine）用于治疗胶质母细胞瘤和宫颈癌。 Mahanimbine在不同遗传状态的19个细胞中表现出针对淋巴样白血病，骨髓性白血病，神经胶质瘤，宫颈癌，胰腺癌，结肠癌和肺癌的抗癌活性。 C-3羟基和NH基团是它们的细胞毒性的负责贡献的组。 Mahanine降低了子宫颈癌中顺铂和紫杉醇的剂量，显示出更好的疗效，作为辅助化疗药物有用，以降低这两种药物的毒性。 建立了一个新的廉价程序，用于此准备工作。 含有富马那霉素和马哈尼碱的生物碱的乙酸乙酯提取物对胶质瘤和宫颈癌有活性。 Mahanine针对分子伴侣Hsp90，导致多种癌症类型，胶质母细胞瘤，宫颈癌和胰腺腺癌中的几种Hsp90-客户蛋白的蛋白酶体依赖性降解，而不管其组织来源如何，从而杀死癌细胞。

    PROCESS FOR THE ISOLATION OF ORGANIC COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER
    8.
    发明申请
    PROCESS FOR THE ISOLATION OF ORGANIC COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER 有权
    分离用于治疗癌症的有机化合物的方法

    公开(公告)号：US20130065932A1

    公开(公告)日：2013-03-14

    申请号：US13416930

    申请日：2012-03-09

    申请人： Chitra Mandal ,  Bikas Chandra Pal ,  Kaushik Bhattacharya ,  Suman Kumar Samanta ,  Sayantani Sarkar ,  Ranjita Das

    发明人： Chitra Mandal ,  Bikas Chandra Pal ,  Kaushik Bhattacharya ,  Suman Kumar Samanta ,  Sayantani Sarkar ,  Ranjita Das

    IPC分类号： A61K31/407 ,  A61P35/00 ,  C07D491/052

    CPC分类号： A61K31/407 ,  A61K36/75 ,  A61K2236/39 ,  C07D491/052

    摘要： The present invention relates to two main components, mahanine and mahanimbine (dehydroxy-mahanine) from Murraya koenigii for the treatment of glioblastoma and cervical carcinoma. Mahanimbine exhibited anti-cancer activity against lymphoid leukemia, myeloid leukemia, glioma, cervical carcinoma, pancreatic, colon and lung cancers in nineteen cells of different genetic status. C-3 hydroxy and NH groups are responsible contributing groups for their cytotoxicity. Mahanine reduced the doses of cisplatin and paclitaxel in cervical cancer showing better efficacy and useful as an adjunct chemotherapeutic agent to reduce toxicity these two drugs. A new cheap process for this preparation was established. EtOAc extract containing alkaloids enriched with mahanimbine and mahanine, is active against glioma and cervical cancers. Mahanine is targeting the chaperone Hsp90 which led to the proteasome-dependent degradation of several Hsp90-client proteins in diverse carcinoma types, glioblastoma, cervical carcinoma and pancreatic adenocarcinoma irrespective of their tissue origins thereby killing the cancer cells.

    摘要翻译： 本发明涉及两种主要成分，来自Murraya koenigii的mahanine和mahanimbine（dehydroxy-mahanine）用于治疗胶质母细胞瘤和宫颈癌。 Mahanimbine在不同遗传状态的19个细胞中表现出针对淋巴样白血病，骨髓性白血病，神经胶质瘤，宫颈癌，胰腺癌，结肠癌和肺癌的抗癌活性。 C-3羟基和NH基团是它们的细胞毒性的负责贡献组。 Mahanine降低了子宫颈癌中顺铂和紫杉醇的剂量，显示出更好的疗效，作为辅助化疗药物有用，以降低这两种药物的毒性。 建立了一个新的廉价程序，用于此准备工作。 含有富马那霉素和马哈尼碱的生物碱的乙酸乙酯提取物对胶质瘤和宫颈癌有活性。 Mahanine针对分子伴侣Hsp90，导致多种癌症类型，胶质母细胞瘤，宫颈癌和胰腺腺癌中的几种Hsp90-客户蛋白的蛋白酶体依赖性降解，而不管其组织来源如何，从而杀死癌细胞。